Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD.

Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):192-9. doi: 10.1097/WAD.0000000000000093.

PMID:
25973909
2.

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.

Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD.

Psychopharmacology (Berl). 2012 Feb;219(3):715-25. doi: 10.1007/s00213-011-2393-2. Epub 2011 Jul 12.

PMID:
21748252
3.

Baseline observation carry forward: reasoning, properties, and practical issues.

Shao J, Jordan DC, Pritchett YL.

J Biopharm Stat. 2009 Jul;19(4):672-84. doi: 10.1080/10543400902964118.

PMID:
20183433
4.

The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.

Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A.

J Pain. 2010 Feb;11(2):109-18. doi: 10.1016/j.jpain.2009.06.007. Epub 2009 Aug 8.

PMID:
19665938
5.

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.

Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ.

Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. Review.

PMID:
18408530
6.

Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.

Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ.

J Clin Psychopharmacol. 2007 Dec;27(6):672-6.

PMID:
18004135
7.

Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials.

Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF.

J Womens Health (Larchmt). 2007 Oct;16(8):1145-56.

PMID:
17937567
8.

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, Iyengar S, Chappell AS.

Pain Med. 2007 Sep;8(6):503-13.

PMID:
17716324
9.

Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.

Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ.

Pain Med. 2007 Jul-Aug;8(5):397-409.

PMID:
17661853
10.
11.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
12.

Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.

Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, Chappell AS.

Diabetes Care. 2007 Mar;30(3):664-9.

PMID:
17327338
13.

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J.

Neurology. 2006 Oct 24;67(8):1411-20.

PMID:
17060567
14.

Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.

Raskin J, Wang F, Pritchett YL, Goldstein DJ.

Pain Med. 2006 Sep-Oct;7(5):373-85.

PMID:
17014595
15.

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

Perahia DG, Pritchett YL, Desaiah D, Raskin J.

Int Clin Psychopharmacol. 2006 Nov;21(6):311-7. Review.

PMID:
17012978
16.

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

Wernicke JF, Raskin J, Rosen A, Pritchett YL, D'Souza DN, Iyengar S, Knopp K, Le TK.

Curr Ther Res Clin Exp. 2006 Sep;67(5):283-304. doi: 10.1016/j.curtheres.2006.10.001.

17.

Use of effect size to determine optimal dose of duloxetine in major depressive disorder.

Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):311-8. Epub 2006 Aug 28.

PMID:
16934840
18.

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.

Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF.

J Palliat Med. 2006 Feb;9(1):29-40.

PMID:
16430342
19.

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF.

Pain. 2005 Dec 15;119(1-3):5-15. Epub 2005 Nov 17.

PMID:
16298061
20.

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF.

Pain Med. 2005 Sep-Oct;6(5):346-56.

PMID:
16266355

Supplemental Content

Loading ...
Support Center